The Charnolosome as a Novel Nanothereranostic Biomarker

Section I: General Topics

1. Transcriptional regulation of Charnolosome through gene/base-editing

2. Charnolosome destabilization induces inflammasome activation

3. Charnolosome in Charnoly Body molecular pathogenesis of gene-manipulated cells and animals

4. Charnolosome and inflammasome in chronic MDR diseases

5. Charnolosome stabilization inhibits inflammasome to confer personalized nanotheranostic benefit in chronic MDR diseases

6. Endogenous, natural, and synthetic antioxidants stabilize charnolosome and its exocytosis to confer theranostic benefit by inflammasome inhibition

7. Charnolosome stability index (stabilized Charnolosome vs activated inflammasome) determines normal cellular function to remain healthy

8. Charnolosome stability index regulates Charnoly Body molecular pathogenesis

9. Nanotheranostic significance of antioxidants in Charnolosome detoxification

10. Theranostic significance of Charnolosome in personalized nanomedicine

11. Environmental toxins and transcriptional regulation of Charnolosome

12. Antioxidants-mediated Charnolosome transcriptional regulation in health and disease

13. Mitochondrial bioenergetics, Charnosome, and theranostic potential of antioxidants

14. Cellular, molecular, and genetic significance of metallothioneins as Charnolosome modulators

15. Pharmacogenomics of metallothioneins and other endogenous, natural, and synthetic antioxidants as CS Regulators in health and disease

16. Environmental pollution and metal ion speciation of metallothioneins

17. Metallothioneins as potential charnolopharmacotherapeutics

18. Antioxidants as Charnolosome stabilizers, charnolophagy enhancers, and intracellular detoxifiers.

19. Charnolosomaging triggers inflammaging to induce charnoptosis, pyroptosis, and ferroptosis in chronic MDR diseases in aging

20. Charnolosome as a theranostic biomarker in cell therapy and nanomedicine

Section II: Special Topics
Part 1: Malnutrition, Stress, Inflammation, Microbial Infections, and Ionizing Radiation Injuries

21. Charnolosome in malnutrition

22. Charnolosome in stress

23. Charnolosome in inflammation

24. Charnolosome in microbial infections

25. Charnolosome in ionizing radiation injuries

Part 2: Congenital & Metabolic Diseases

26. Charnolosome in congenital diseases

27. Charnolosome in metabolic diseases

28. Charnolosome in hyperlipidemia

29. Charnolosome in obesity

30. Charnolosome in diabetes

31. Charnolosome in hepatic diseases

32. Charnolosome in GIT diseases

Part 3: Multidrug-Resistant Systemic Diseases

33. Charnolosome in skin diseases

34. Charnolosome in musculo-skeletal diseases

35. Charnolosome in pulmonary diseases

36. Charnolosome in cardiovascular diseases

37. Charnolosome in renal diseases

38. Charnolosome in reproductive diseases

Part 4: Neuropsychiatric & Neurodegenerative Diseases

39. Charnolosome in polysubstance abuse

40. Charnolosome in neuropsychiatric diseases

41. Charnolosome in neurodegenerative diseases

42. Charnolosome in Neurodegenerative α-Synucleinopathies

43. Charnolosome in Parkinson’s Disease

44. Charnolosome in Alzheimer’s Disease and other taupathies

45. Charnolosome in stroke & traumatic brain injury

46. Attenuation of Charnolosome-Mediated Neurodegenerative α-Synucleinopathies by antioxidants

47. Charnolosome as a novel nanotheranostic biomarker of aging

Part 5: Inflammatory Diseases, Autoimmune Diseases, Cancer, & Infectious Diseases

48. Charnolosome in Inflammatory Diseases

49. Charnolosome in autoimmune diseases

50. Charnolosome in cancer

51. Charnolosome in infectious diseases

Section III: Future Prospects

52. Charnolosomics in nanomedicine (Recent Update)

53. Charnolosome-based disease-specific nanopharmacotherapeutics

54. Physiological, Biochemical, Pharmacological, and Genetic Manipulation of Charnolosome in Personalized Nanotheranostics of Chronic MDR Diseases

55. Transcriptional and translational regulation of Charnolosome in multi-drug resistant malignancies and other chronic diseases

56. Future prospectus of Charnolosome in evidence-based personalized nanotheranostics